6-K - NewcelX Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NewcelX Ltd. announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. to advance its lead program NCEL-101 for Type 1 Diabetes by integrating stem-cell-derived islets with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart. The collaboration leverages Eledon's clinical experience from over 100 transplant patients to support durable graft survival and a potential functional cure.

Key Takeaways

1Strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN)

2Advances NCEL-101 program integrating with tegoprubart (AT-1501)

3Eledon has treated over 100 transplant patients under multiple FDA-cleared IND applications

4NCEL-101 is NewcelX's core stem-cell-derived therapy for Type 1 Diabetes

5Quotes from CSO Michel Revel and CEO Ronen Twito highlight strategic milestone and regulatory pathway benefits

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Transaction Details

Material Agreement

Parties: NewcelX Ltd., Eledon Pharmaceuticals, Inc.

•Collaborative research agreement to advance combination strategies integrating NCEL-101 with tegoprubart (AT-1501)
•Supports durable, immune-protected islet replacement for Type 1 Diabetes
•Leverages clinical experience from over 100 transplant patients
•Intended to accelerate timelines, establish regulatory pathway, and enhance development visibility

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE TITLED: "NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS (NASDAQ: ELDN) TO ADVANCE NCEL-101 PROGRAM FOR TYPE 1 DIABETES."